Annual Long Term Debt
$217.09 M
+$153.06 M+239.05%
December 1, 2023
Summary
- As of February 8, 2025, SVA annual long term debt is $217.09 million, with the most recent change of +$153.06 million (+239.05%) on December 1, 2023.
- During the last 3 years, SVA annual long term debt has risen by +$123.31 million (+131.50%).
- SVA annual long term debt is now at all-time high.
Performance
SVA Long Term Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Long Term Debt
$142.71 M
-$74.38 M-34.26%
June 1, 2024
Summary
- As of February 8, 2025, SVA quarterly long term debt is $142.71 million, with the most recent change of -$74.38 million (-34.26%) on June 1, 2024.
- Over the past year, SVA quarterly long term debt has increased by +$90.79 million (+174.87%).
- SVA quarterly long term debt is now -34.26% below its all-time high of $217.09 million, reached on December 1, 2023.
Performance
SVA Quarterly Long Term Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Long Term Debt Formula
Long-Term Debt = Bonds Payable + Long-Term Loans + Mortgage Payable + Other Long-Term Borrowings − Current Portion of Long-Term Debt
SVA Long Term Debt Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +239.1% | +174.9% |
3 y3 years | +131.5% | +10.6% |
5 y5 years | +1949.0% | +1883.7% |
SVA Long Term Debt Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | at high | +239.1% | -34.3% | +174.9% |
5 y | 5-year | at high | +2917.6% | -34.3% | +1926.5% |
alltime | all time | at high | >+9999.0% | -34.3% | >+9999.0% |
Sinovac Biotech Long Term Debt History
Date | Annual | Quarterly |
---|---|---|
Jun 2024 | - | $142.71 M(-34.3%) |
Dec 2023 | $217.09 M(+239.0%) | $217.09 M(+318.1%) |
Jun 2023 | - | $51.92 M(-18.9%) |
Dec 2022 | $64.03 M(-50.7%) | $64.03 M(-13.2%) |
Jun 2022 | - | $73.75 M(-43.2%) |
Dec 2021 | $129.84 M(+38.5%) | $129.84 M(+0.7%) |
Jun 2021 | - | $129.00 M(+37.6%) |
Dec 2020 | $93.77 M(+1203.5%) | $93.77 M(+16.2%) |
Sep 2020 | - | $80.73 M(+13.2%) |
Jun 2020 | - | $71.29 M(+912.4%) |
Mar 2020 | - | $7.04 M(-2.1%) |
Dec 2019 | $7.19 M(-32.1%) | $7.19 M(-49.0%) |
Sep 2019 | - | $14.11 M(+7.3%) |
Jun 2019 | - | $13.14 M(-16.3%) |
Mar 2019 | - | $15.70 M(+48.1%) |
Dec 2018 | $10.60 M(-51.7%) | $10.60 M(-46.1%) |
Jun 2018 | - | $19.64 M(-10.4%) |
Dec 2017 | $21.92 M(+132.0%) | $21.92 M(+78.1%) |
Jun 2017 | - | $12.31 M(+30.3%) |
Dec 2016 | $9.45 M(+1149.7%) | $9.45 M(+58.8%) |
Sep 2016 | - | $5.95 M(+101.3%) |
Jun 2016 | - | $2.96 M(+9.0%) |
Mar 2016 | - | $2.71 M(+258.9%) |
Dec 2015 | $756.00 K(-58.1%) | $756.00 K(-1.9%) |
Sep 2015 | - | $771.00 K(-57.2%) |
Dec 2014 | $1.80 M(-94.4%) | $1.80 M(-84.7%) |
Sep 2014 | - | $11.80 M(+1.3%) |
Jun 2014 | - | $11.65 M(-33.4%) |
Mar 2014 | - | $17.50 M(-45.6%) |
Dec 2013 | $32.15 M | $32.15 M(-11.3%) |
Sep 2013 | - | $36.23 M(-15.2%) |
Date | Annual | Quarterly |
---|---|---|
Jun 2013 | - | $42.70 M(+8.2%) |
Mar 2013 | - | $39.46 M(+14.7%) |
Dec 2012 | $34.41 M(+98.7%) | $34.41 M(+39.5%) |
Sep 2012 | - | $24.67 M(+5.7%) |
Jun 2012 | - | $23.33 M(+19.9%) |
Mar 2012 | - | $19.45 M(+12.3%) |
Dec 2011 | $17.32 M(+72.2%) | $17.32 M(+19.9%) |
Sep 2011 | - | $14.45 M(+18.5%) |
Jun 2011 | - | $12.19 M(+20.1%) |
Mar 2011 | - | $10.15 M(+0.9%) |
Dec 2010 | $10.06 M(+359.6%) | $10.06 M(+13.6%) |
Sep 2010 | - | $8.85 M(+6.7%) |
Jun 2010 | - | $8.30 M(-4.3%) |
Mar 2010 | - | $8.67 M(+295.8%) |
Jun 2009 | - | $2.19 M(+0.0%) |
Mar 2009 | - | $2.19 M(+0.1%) |
Dec 2008 | $2.19 M(-46.6%) | $2.19 M(-40.0%) |
Sep 2008 | - | $3.65 M(+150.6%) |
Jun 2008 | - | $1.46 M(-65.9%) |
Mar 2008 | - | $4.27 M(+4.2%) |
Dec 2007 | $4.10 M(+6.9%) | $4.10 M(+4.2%) |
Jun 2007 | - | $3.93 M(+2.5%) |
Dec 2006 | $3.84 M(+44.1%) | $3.84 M(+53.5%) |
Jun 2006 | - | $2.50 M(-6.2%) |
Dec 2005 | $2.66 M(+1216.2%) | $2.66 M(+1289.6%) |
Jun 2005 | - | $191.70 K(-5.3%) |
Dec 2004 | $202.40 K(-66.5%) | $202.40 K(-85.5%) |
Sep 2004 | - | $1.40 M(-34.2%) |
Jun 2004 | - | $2.12 M(+251.3%) |
Dec 2003 | $603.90 K(+238.1%) | $603.90 K |
Apr 2001 | $178.60 K(-63.9%) | - |
Apr 2000 | $495.00 K | - |
FAQ
- What is Sinovac Biotech annual long term debt?
- What is the all time high annual long term debt for Sinovac Biotech?
- What is Sinovac Biotech annual long term debt year-on-year change?
- What is Sinovac Biotech quarterly long term debt?
- What is the all time high quarterly long term debt for Sinovac Biotech?
- What is Sinovac Biotech quarterly long term debt year-on-year change?
What is Sinovac Biotech annual long term debt?
The current annual long term debt of SVA is $217.09 M
What is the all time high annual long term debt for Sinovac Biotech?
Sinovac Biotech all-time high annual long term debt is $217.09 M
What is Sinovac Biotech annual long term debt year-on-year change?
Over the past year, SVA annual long term debt has changed by +$153.06 M (+239.05%)
What is Sinovac Biotech quarterly long term debt?
The current quarterly long term debt of SVA is $142.71 M
What is the all time high quarterly long term debt for Sinovac Biotech?
Sinovac Biotech all-time high quarterly long term debt is $217.09 M
What is Sinovac Biotech quarterly long term debt year-on-year change?
Over the past year, SVA quarterly long term debt has changed by +$90.79 M (+174.87%)